TH9507
Phase 3Small molecule
TH9507 is one of 40 small molecule programs targeting Lipodystrophy. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Jardiance
Boehringer IngelheimPreclinical
TH9507
TTheratechnologies
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TH9507. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTheratechnologies